Anti-AAV Antibodies Exclude 30-70% of Patients and Block Redosing

30-70% of the population has pre-existing antibodies against AAV from natural childhood exposure, making them ineligible for gene therapy. Worse, patients who receive one dose develop strong immunity preventing a second dose — even if the first wears off years later.

NAb seroprevalence: AAV2 (50-70%), AAV8 (30-40%), AAV9 (35-50%). Even low titers (1:5-1:10) ablate transduction. Novel solutions emerging in 2025-2026: (1) AAV.div3A — a chimeric capsid with zero antigenic cross-reactivity and undetectable seroprevalence, showing successful redosing in Pompe disease model; (2) Bispecific antibodies using CD40 blockade and B-cell depletion to prevent anti-AAV responses; (3) Biomimetic artificial enveloped AAV (AEV) vectors shielding from immune recognition; (4) Hansa Biopharma's imlifidase (IgG-cleaving enzyme) to clear existing antibodies before dosing.

Why It Matters

At current seroprevalence, 30-70% are immediately ineligible for any given AAV gene therapy. For rare diseases with small patient pools, this is devastating. Luxturna showed declining efficacy at 5+ years, suggesting redosing may be needed — but is currently impossible.

Startup Approach

Engineer AAV capsids with altered epitopes evading existing NAbs while maintaining tropism. Or develop immunomodulation protocols enabling dosing in seropositive patients and redosing. The AAV.div3A approach (zero cross-reactivity) is immediately licensable.

NIH Funding

SCGE Consortium working group on immune responses. NIAID funds AAV immunology. NHLBI hemophilia programs generate immunology data.

Who's Working On It

Hansa Biopharma (imlifidase/IdeS), Selecta Biosciences (ImmTOR nanoparticles), Spark/Roche (immune-evasive capsids), AAV.div3A researchers (serodivergent capsids, 2025)